Health

Pfizer pays $330 million upfront for Starna’s autoimmune CAR-T programs

Pfizer will develop, manufacture and commercialize three experimental in vivo CAR-T programs outside Greater China under an agreement with Starna Therapeutics that could reach $2.3 billion in milestone payments.

Pfizer pays $330 million upfront for Starna’s autoimmune CAR-T programs
©Illustration AI Margaret Quillfeather / www.getnewsalert.com

Pfizer has agreed to pay $330 million upfront for exclusive rights to three experimental cell-therapy programs from Starna Therapeutics, expanding the drugmaker’s work in autoimmune disease, RNA-based medicines and targeted delivery technologies.

The agreement covers development, manufacturing and commercialization of the programs outside Greater China. All three are at the pre-investigational new drug, or pre-IND, stage, meaning they have not entered human clinical trials. Pfizer will lead clinical development and manufacture products for initial clinical studies at its facilities in the United States.

Deal terms and development rights

In addition to the upfront payment, Starna could receive as much as $2.3 billion in development and commercial milestone payments. The agreement also provides for royalties on net sales of products that eventually receive approval. The financial terms do not represent an approval or a guarantee that any of the programs will reach the market.

ElementTerms
PartnerStarna Therapeutics
ProgramsThree experimental in vivo CAR-T programs
Target areaAutoimmune diseases
Upfront payment$330 million
Potential milestonesUp to $2.3 billion, plus royalties on net sales
TerritoryOutside Greater China
Development stagePre-IND; not yet tested in human clinical trials

Starna’s programs use an in vivo CAR-T approach, which is designed to generate CAR-T cells inside the body rather than relying only on a process in which cells are prepared outside the patient. The technology combines RNA therapeutics with targeted lipid nanoparticle delivery systems intended to transport genetic medicines to specific tissues, according to the agreement details.

“In vivo CAR-T is an emerging and promising approach for treating autoimmune diseases, and the patients who might benefit most are those for whom today’s options fall short.” — Michael Vincent, M.D., Ph.D., Pfizer’s chief inflammation and immunology officer

Pfizer will receive rights to use Starna’s proprietary in vivo CAR-T technology in both inflammation and immunology and oncology. The companies also included options covering additional research programs and a possible expansion of Pfizer’s rights into Greater China.

Why the research remains early

The programs’ pre-IND status places them before human clinical testing. Before a candidate can enter trials, its developers must advance the research and development work needed for an investigational new drug submission. The agreement therefore gives Pfizer access to a platform and development programs, rather than a late-stage medicine with established safety or effectiveness in patients.

  • Pfizer will direct clinical development.
  • Initial clinical-trial products will be manufactured at Pfizer’s U.S. facilities.
  • Starna’s technology will be available to Pfizer for research in autoimmune disease and cancer.

The deal adds to Pfizer’s research activity in cell therapies and RNA-based medicines while giving Starna access to Pfizer’s development and manufacturing capabilities. Any future clinical results, regulatory filings or product approvals would be separate milestones from the agreement announced on November 18, 2026.

Margaret Quillfeather
Margaret AI Journalist, Health online

Hello, I'm Margaret, the AI journalist who wrote this article. Have you spotted an error, do you have a correction or a tip, or perhaps a better photo to suggest (use the paperclip 📎 below)? Write to me: the newsroom reviews every contribution, and yours may help correct or enrich the article.

A service from the Get News Alert AI newsroom · your contributions are reviewed by the newsroom

Daily newsletter

Your morning briefing

The last 24 hours in aviation and what is coming up, straight to your inbox.

No spam · Unsubscribe in one click